Foundayo cut sleep apnea events by 44% without PAP. Can Lilly turn an obesity pill into its next OSA franchise?
Foundayo cut sleep apnea events by up to 44% in Phase 3 ATTAIN-OSA, giving Eli Lilly another potential obesity-linked OSA treatment.
Pharma & Biotech
Pharma & Biotech
Lilly’s retatrutide cut knee pain as weight fell nearly 29%, but the Phase 3 result raises a bigger osteoarthritis question
Lilly’s retatrutide cut weight by up to 28.7% and significantly reduced knee osteoarthritis pain, but dose and safety trade-offs now matter.
Features & Analysis
Can branded GLP-1 medicines replace compounded weight-loss drugs in Hims & Hers growth strategy?
Lilly is bringing Zepbound and Foundayo to Hims & Hers, turning a former GLP-1 disruptor into a branded obesity-drug distribution channel.
Pharma & Biotech
Eli Lilly brings Zepbound and Foundayo to Hims & Hers, but who gains most from the deal?
Eli Lilly and Hims & Hers expand access to Zepbound and Foundayo from $149 monthly. Discover the impact on obesity medicine distribution.
Pharma & Biotech
Eli Lilly’s TOGETHER-PsO trial links obesity treatment with psoriasis improvement
Eli Lilly's Taltz and Zepbound show broader immune and metabolic biomarker changes in psoriasis, building on Phase 3b skin clearance results.
Pharma & Biotech
Lilly’s Zepbound plus Taltz sustains stronger psoriasis and psoriatic arthritis outcomes at one year
Eli Lilly and Company says one-year Phase 3b data from TOGETHER-PsO and TOGETHER-PsA show sustained or deeper improvements when Zepbound and Taltz are used together in patients living with psoriatic disease and obesity.
Pharma & Biotech
Mounjaro is no longer just about blood sugar and weight. FDA approval pushes Lilly into a bigger cardiovascular fight
The FDA has approved Eli Lilly and Company’s Mounjaro to reduce cardiovascular death, heart attack and stroke risk in high-risk adults with type 2 diabetes, significantly broadening the clinical case for tirzepatide beyond glucose control and weight reduction.
Pharma & Biotech
Can Ascletis ASC37 become a once-monthly triple agonist for obesity?
Ascletis says ASC37 beat tirzepatide in obese mice, but human dosing, safety and durability remain untested ahead of a planned U.S. IND.
Pharma & Biotech
Evidation GLP-1 study reveals major growth runway but exposes widening access gaps
Discover how Evidation’s 165,000-person study reveals GLP-1 growth potential, access gaps and persistence risks shaping obesity care. Read more.
Pharma & Biotech
Kalohexis 710GO data highlight a differentiated obesity mechanism as Phase 1 moves ahead
Read how Kalohexis’ 710GO could challenge GLP-1 obesity drugs with dual MC3R/MC4R activation, lean-mass sparing and durability.